Status:
TERMINATED
Exploring Genomic, Proteomic and Dosimetric Determinants of Late Toxicity After Three Dimensional Conformal Radiotherapy (RT) for Prostate Cancer
Lead Sponsor:
AHS Cancer Control Alberta
Conditions:
Prostate Cancer
Eligibility:
MALE
Brief Summary
Prostate cancer is the most common malignancy in males, and radiotherapy is a commonly chosen treatment option for patients with localized disease. Technical innovations such as three-dimensional conf...
Detailed Description
OBJECTIVES: Major innovations in radiotherapy (RT) delivery (3D conformal RT, intensity modulated RT) now permit RT dose escalation to be tested as a means of improving control of localized prostate c...
Eligibility Criteria
Inclusion
- Treatment with 3D CRT for which follow-up toxicity evaluation was done
Exclusion
- Follow-up less than 18 months
Key Trial Info
Start Date :
April 1 2003
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2012
Estimated Enrollment :
83 Patients enrolled
Trial Details
Trial ID
NCT00122265
Start Date
April 1 2003
End Date
January 1 2012
Last Update
February 26 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2